Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03884439 |
Recruitment Status :
Enrolling by invitation
First Posted : March 21, 2019
Last Update Posted : April 4, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Crohn's Disease Ulcerative Colitis | Drug: Infliximab [infliximab biosimilar 3] |
This study will be conducted with all-case investigation system in patients with Crohn's disease or ulcerative colitis.
This study will be conducted in patients who used this drug after the day of approval of dosage and administration for Crohn's disease or ulcerative colitis at contracted medical institutions. Patients who used this drug before conclusion of the contract with the medical institution will also be included in this study (retrospective patients will be included).
Therefore, Time Perspective is retrospective and prospective.
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Case-Only |
Time Perspective: | Other |
Official Title: | Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Crohn's Disease or Ulcerative Colitis) |
Actual Study Start Date : | March 18, 2019 |
Estimated Primary Completion Date : | February 13, 2024 |
Estimated Study Completion Date : | February 13, 2024 |

Group/Cohort | Intervention/treatment |
---|---|
Infliximab [infliximab biosimilar 3]
Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
|
Drug: Infliximab [infliximab biosimilar 3]
<Crohn's disease> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. <Ulcerative colitis> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
Other Name: Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" |
- Incidence of adverse drug reactions [ Time Frame: 30 weeks from the day of initial dose ]
- Percentage of Participants With Remission (Clinical Disease Activity Index (CDAI)) for Crohn's disease [ Time Frame: Week 30 ]
- Percentage of Participants With Improvement (Clinical Disease Activity Index (CDAI)) for Crohn's disease [ Time Frame: Week 30 ]
- Percentage of Participants With Remission (Mayo) score for ulcerative colitis [ Time Frame: Week 30 ]
- Percentage of Participants With Improvement (Mayo) score for ulcerative colitis [ Time Frame: Week 30 ]
- Partial mayo Score [ Time Frame: Baseline, Week 30 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with Crohn's disease or ulcerative colitis who started treatment with this drug
- Patients who received this drug for the first time at the medical institution after the day of launch of this drug.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03884439
Japan | |
Pfizer Local Country Office | |
Tokyo, Japan |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT03884439 |
Other Study ID Numbers: |
B5371008 |
First Posted: | March 21, 2019 Key Record Dates |
Last Update Posted: | April 4, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
Crohn's Disease Ulcerative Colitis Infliximab biosimilar |
Crohn Disease Colitis Colitis, Ulcerative Ulcer Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
Intestinal Diseases Colonic Diseases Pathologic Processes Infliximab Dermatologic Agents Gastrointestinal Agents Antirheumatic Agents |